Business Context and Reporting Period
This Form 8-K Current Report was filed by Sanara Medtech Inc. (SMTI) on September 19, 2024. The filing discloses the execution of a formal employment agreement with Ronald T. Nixon, who was previously appointed as Chief Executive Officer (CEO) on May 12, 2024. The agreement is effective as of September 1, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes and Compensation Terms
The primary material change is the formalization of the CEO's compensation package under a new one-year employment agreement with automatic successive one-year renewals. Key terms include:
- Base Salary: $350,000 annually, subject to periodic adjustment by the Compensation Committee.
- Equity Awards: Eligible for an annual award of restricted common stock up to 75% of base salary and an annual performance-based award of restricted stock up to $625,000.
- Cash Bonuses: Eligible for an annual cash bonus up to 75% of base salary based on performance metrics, plus a one-time cash bonus of $125,000 payable on the first regular payroll date following the execution date.
- Severance Provisions:
- Termination without "Cause" or for "Good Reason": One year of base salary.
- Termination within one year of a "Change of Control": Two years of base salary.
- Severance payments are made in 24 equal semi-monthly installments and include accelerated vesting of prior stock awards and continued health benefits (including COBRA premium reimbursement).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding business operations. The agreement includes standard provisions for confidentiality, non-competition, non-solicitation, and non-interference. Severance benefits are contingent upon the executive executing a release of claims.
Investor Verification Checklist
- Verify the exact payment date for the $125,000 one-time cash bonus based on the company's payroll schedule.
- Review the specific performance metrics required to trigger the annual cash bonus and the $625,000 performance-based stock award.
- Examine the full text of the Employment Agreement (Exhibit 10.1) for precise definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the total potential equity dilution impact from the annual restricted stock awards.